Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board March 12, 2015
Live imaging reveals a new role for the sigma-1 (σ1) receptor in allowing microglia to leave brain injuries March 11, 2015
Anavex Appoints Scientific Advisory Board Member with Expertise in Protein Misfolding Neurodegenerative Diseases March 5, 2015
ANAVEX 2-73 Could Prevent Alzheimer’s Disease in Addition to Modifying and Treating Symptoms February 25, 2015
Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp. February 18, 2015
Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases February 9, 2015
Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model. January 20, 2015
